Cargando…

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koyama, Takafumi, Shimizu, Toshio, Iwasa, Satoru, Fujiwara, Yutaka, Kondo, Shunsuke, Kitano, Shigehisa, Yonemori, Kan, Shimomura, Akihiko, Iizumi, Sakura, Sasaki, Tatsuya, Furuse, Junji, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004556/ https://www.ncbi.nlm.nih.gov/pubmed/31797489 http://dx.doi.org/10.1111/cas.14265

Ejemplares similares

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Computer centre of CERN : the IBM7090
por: CERN PhotoLab
Publicado: (1963)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

Reference manual 709/7090 Fortran programming system
por: International Business Machines. New York
Publicado: (1958)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

IBM 7090/7094 programming systems: Fortran IV language
por: International Business Machines. New York
Publicado: (1963)

SCOPT: an IBM 7090 code for beam optics problems on the synchro-cyclotron
por: Skarek, Paul
Publicado: (1964)

IBM general information manual: 709-7090 data processing systems
por: International Business Machines. New York
Publicado: (1959)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
por: Takahashi, Shunji, et al.
Publicado: (2021)

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study
por: Kawai, Akira, et al.
Publicado: (2021)

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
por: Shimizu, Toshio, et al.
Publicado: (2022)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

Focusing and magnification ratio adjustments with quadrupole triplets and doublets: Programme for the IBM 7090
por: Madsen, J H B
Publicado: (1964)

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors
por: Fujiwara, Yutaka, et al.
Publicado: (2021)

Reference manual IBM 709/7090 programming systems: Fortran assembly program (FAP)
por: International Business Machines. New York
Publicado: (1962)

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Chiba, Yohei, et al.
Publicado: (2022)

ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Takahashi, Masamichi, et al.
Publicado: (2021)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Magnet shimming: an IBM-7090 code utilizing empirical data to obtain optimal shimming and trimming of magnets
por: Vogt-Nilsen, Nils
Publicado: (1964)

Clinical Development of Immune Checkpoint Inhibitors
por: Ito, Ayumu, et al.
Publicado: (2015)

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
por: Sunami, Kuniko, et al.
Publicado: (2019)

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i9bfa26s2p2jkg3qvdd38vrpqs